Developing a gene expression signature for first-line treatment in metastatic CRC
Tempus RWD identifies a signature predictive of bevacizumab response in CRC
rwPFS performance of a gene signature on a test set of 1L FOLFOX+BEV treated patients (N=132). Patients were stratified into High/Low based on the median of the training set. No significant difference was observed in the test set of FOLFOX-treated patients (N=86)*.
*data not shown
Lens Library
